Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S.

2 July 2018

Helsinn Group and Angelini support Satellite Symposium at MASCC/ISOO 2018 Annual Meeting

26 June 2018

38th Ordinary General Meeting of Farma Industria Ticino

18 June 2018

Second Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Rajiv Agarwal, MD, Memorial Sloan Kettering Cancer Center

5 June 2018

Linnea obtained the Certificate of Suitability (CEP) for hyoscine butylbromide released by EDQM

30 May 2018

Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for standard induction chemotherapy

30 May 2018

Helsinn announces EUR6 million investment in Helsinn Birex Pharmaceuticals to safeguard the quality and authenticity of its products

24 May 2018

CPhI Worldwide 2018 – Madrid, 9 – 11 October 2018

15 May 2018

Zambon Group SA: Zcube launches the third edition of Open Accelerator, the programme for projects in the Central Nervous System and Respiratory areas

14 May 2018

Helsinn Group announces the launch of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the United States

8 May 2018